Regulus Therapeutics (NASDAQ:RGLS) Now Covered by Leerink Swann

Leerink Swann assumed coverage on shares of Regulus Therapeutics (NASDAQ:RGLS) in a research note published on Friday, January 5th, MarketBeat reports. The firm issued an outperform rating and a $2.00 target price on the biopharmaceutical company’s stock.

RGLS has been the topic of several other reports. Needham & Company LLC restated a hold rating on shares of Regulus Therapeutics in a report on Tuesday, November 14th. Zacks Investment Research downgraded Regulus Therapeutics from a buy rating to a hold rating in a report on Tuesday, September 19th. Finally, Wedbush reiterated an outperform rating and issued a $4.00 price target on shares of Regulus Therapeutics in a report on Monday, December 11th. One analyst has rated the stock with a sell rating, five have issued a hold rating and four have assigned a buy rating to the stock. Regulus Therapeutics has a consensus rating of Hold and an average target price of $2.46.

Shares of Regulus Therapeutics (RGLS) opened at $1.23 on Friday. The company has a debt-to-equity ratio of 0.41, a quick ratio of 6.77 and a current ratio of 6.77. The company has a market capitalization of $127.86, a PE ratio of -0.91 and a beta of 1.55. Regulus Therapeutics has a 52-week low of $0.79 and a 52-week high of $2.60.

Regulus Therapeutics (NASDAQ:RGLS) last released its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.18) EPS for the quarter, hitting the consensus estimate of ($0.18). Regulus Therapeutics had a negative return on equity of 189.71% and a negative net margin of 107,606.96%. analysts expect that Regulus Therapeutics will post -1.03 earnings per share for the current year.

A number of hedge funds have recently made changes to their positions in RGLS. Quantitative Investment Management LLC acquired a new position in Regulus Therapeutics during the 2nd quarter worth $103,000. GSA Capital Partners LLP acquired a new position in Regulus Therapeutics during the 2nd quarter worth $139,000. Royal Bank of Canada lifted its holdings in shares of Regulus Therapeutics by 12.1% in the second quarter. Royal Bank of Canada now owns 184,040 shares of the biopharmaceutical company’s stock valued at $182,000 after buying an additional 19,934 shares during the period. Victory Capital Management Inc. acquired a new stake in shares of Regulus Therapeutics in the third quarter valued at $347,000. Finally, Goldman Sachs Group Inc. lifted its holdings in shares of Regulus Therapeutics by 189.1% in the second quarter. Goldman Sachs Group Inc. now owns 368,285 shares of the biopharmaceutical company’s stock valued at $363,000 after buying an additional 240,890 shares during the period. Institutional investors own 59.39% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Regulus Therapeutics (NASDAQ:RGLS) Now Covered by Leerink Swann” was originally posted by BBNS and is owned by of BBNS. If you are accessing this story on another domain, it was stolen and republished in violation of international copyright and trademark legislation. The legal version of this story can be viewed at https://baseballnewssource.com/markets/leerink-swann-initiates-coverage-on-regulus-therapeutics-rgls/1819936.html.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.

Analyst Recommendations for Regulus Therapeutics (NASDAQ:RGLS)

Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Rumor: Milwaukee Brewers Offer Yu Darvish Contract
Rumor: Milwaukee Brewers Offer Yu Darvish Contract
Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Houston Astros Add Starter to Rotation
Houston Astros Add Starter to Rotation
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Justin Morneau Former Star With Twins and AL MVP Retires
Justin Morneau Former Star With Twins and AL MVP Retires


Leave a Reply

 
© 2006-2018 BBNS.